News

Sprint Bioscience, a fragment based drug discovery company, is growing its CRO business and speeds up the development of their in-house cancer metabolism pipe line. In alliance with the company expansion, we are happy to welcome three new colleagues; Anne-Marie … Continue reading →

Sprint Bioscience attends Partnering at BIO-Europe® 2011  in Dusseldorf, Germany, October 31 – November 2.

New review article in Current Opinion in Chemical Biology co-authored by Sprint Bioscience CEO, Dr. Anders Åberg http://www.sciencedirect.com/science/article/pii/S1367593111001013

“Autophagy, the process of “self-eating” within cells, has been controversial in cancer since it was first linked to the disease in 1999. Because autophagy can either suppress or promote tumors, depending on the context. A consensus is emerging that it’s the … Continue reading →

Sprint Bioscience attends Bio-Europe spring 2011 in Milan. The conference is a major partnering event within the pharmaceutical industry with over 1000 companies attending. Sprint Bioscience will meet over 20 companies to discuss its gene-to-lead service as well as the … Continue reading →

Kancera AB was listed on NASDAQ OMX First North on february 25 2011 after  a successful issue of shares. Sprint Bioscience owns about 10% of Kancera

The lead generation company Sprint Bioscience brings in venture capital from Första Entreprenörsfonden and Almi Invest for their development of lead compounds for research projects within the pharmaceutical industry. Sprint Bioscience is a provider of innovative and patentable solutions for … Continue reading →

Sprint Bioscience sells a cancer metabolism project to Kancera AB